Dova Pharmaceuticals (DOVA) Given Consensus Rating of “Hold” by Brokerages

Shares of Dova Pharmaceuticals (NASDAQ:DOVA) have been assigned an average recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $32.25.

DOVA has been the topic of several analyst reports. BidaskClub upgraded shares of Dova Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday. ValuEngine upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Evercore ISI initiated coverage on shares of Dova Pharmaceuticals in a report on Friday, March 23rd. They issued a “line” rating and a $29.00 price objective for the company. Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 14th. Finally, Ladenburg Thalmann initiated coverage on shares of Dova Pharmaceuticals in a report on Thursday, April 26th. They issued a “buy” rating for the company.

Shares of NASDAQ:DOVA traded up $1.19 during trading hours on Friday, hitting $27.84. The stock had a trading volume of 343,660 shares, compared to its average volume of 217,506. Dova Pharmaceuticals has a 1-year low of $16.98 and a 1-year high of $37.00. The firm has a market capitalization of $751.30 million and a P/E ratio of -19.89.

Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings results on Wednesday, May 9th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.05). sell-side analysts anticipate that Dova Pharmaceuticals will post -2.15 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Nexthera Capital LP boosted its holdings in shares of Dova Pharmaceuticals by 25.4% in the first quarter. Nexthera Capital LP now owns 568,243 shares of the company’s stock valued at $15,411,000 after acquiring an additional 115,211 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Dova Pharmaceuticals in the first quarter valued at approximately $220,000. venBio Select Advisor LLC bought a new position in shares of Dova Pharmaceuticals in the first quarter valued at approximately $3,390,000. Pier Capital LLC boosted its holdings in shares of Dova Pharmaceuticals by 36.1% in the first quarter. Pier Capital LLC now owns 217,885 shares of the company’s stock valued at $5,909,000 after acquiring an additional 57,762 shares in the last quarter. Finally, Citigroup Inc. boosted its holdings in shares of Dova Pharmaceuticals by 4,519.6% in the first quarter. Citigroup Inc. now owns 65,968 shares of the company’s stock valued at $1,789,000 after acquiring an additional 64,540 shares in the last quarter. Institutional investors and hedge funds own 26.66% of the company’s stock.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply